Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01756157 · ClinicalTrials.gov registry record · Phase 2
Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks
A Phase 2 study, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT01756157 is a Phase 2 study that has completed, run by Shire. The registered enrollment target is 47 participants.
The verdict
NCT01756157, a Phase 2 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The primary objectives of the study are to evaluate the safety, tolerability, and efficacy of two doses of CINRYZE with recombinant human hyaluronidase (rHuPH20) administered by subcutaneous (SC) injection to prevent angioedema attacks.
Interventions
- BIOLOGICAL CINRYZE with rHuPH20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2013-02-04 |
| Est. Completion | 2013-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01756157
The ClinicalTrials.gov registry entry for NCT01756157 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CINRYZE with rHuPH20 is the first listed.
NCT01756157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01756157 about?
NCT01756157 is a clinical study titled "Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks". The primary objectives of the study are to evaluate the safety, tolerability, and efficacy of two doses of CINRYZE with recombinant human hyaluronidase (rHuPH20) administered by subcutaneous (SC) injection to prevent angioedema attacks.
What is the current status of trial NCT01756157?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2013-02-04. Estimated completion is 2013-09-13.
What interventions are being tested in trial NCT01756157?
The interventions under investigation include: CINRYZE with rHuPH20 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01756157?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.